Hypoxia-active nanoparticles used in tumor theranostic.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Tumor hypoxia is a key factor in cancer aggressiveness and poor treatment outcomes.
• Effective targeting and elimination of hypoxic tumor cells are critical for cancer therapy.
• Developing novel strategies for imaging and treating hypoxic tumors is an active research area.

Purpose of the Study:

• To review recent advancements in hypoxia-activated prodrugs and their nanoparticle formulations for tumor-targeted therapy.
• To highlight the potential of hypoxia-responsive nanoparticles in enhancing cancer treatment modalities.
• To discuss the advantages of targeting tumor hypoxia over specific receptors for overcoming tumor heterogeneity.

Main Methods:

• Review of published literature on hypoxia-activated prodrugs and nanoparticles.
• Analysis of nanoparticle behavior under hypoxic conditions within the tumor microenvironment.
• Evaluation of nanoparticle efficacy in various imaging and therapeutic applications.

Main Results:

• Hypoxia-active nanoparticles are inactive in circulation but activated by tumor hypoxia.
• These nanoparticles enhance chemotherapy, radiotherapy, and imaging modalities (fluorescence, photoacoustic).
• Targeting tumor hypoxia offers a broad applicability across various solid tumors, overcoming heterogeneity.

Conclusions:

• Hypoxia-activated nanoparticles represent a significant advancement in targeted cancer therapy.
• Their ability to respond to the tumor microenvironment allows for enhanced therapeutic and diagnostic outcomes.
• This approach holds promise for developing effective treatments for a wide range of solid tumors.